Substituted 2-alkyl-1-OXO-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies

US9416124B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9416124-B2
Application numberUS-201214240994-A
CountryUS
Kind codeB2
Filing dateAug 24, 2012
Priority dateAug 25, 2011
Publication dateAug 16, 2016
Grant dateAug 16, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl -1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having a structure represented by a formula: wherein Ar 1 is selected from 3-pyridinyl, 4-isoxazolyl, N-methyl-4-pyrazolyl, 4-pyrazolyl, 4-isothiazolyl, 5-thiazolyl, 5-pyrimidinyl, or 4-pyridazinyl; R 1 is selected from CF 3 , (CH 3 ) 2 CH or cyclopropyl, R 2 and R 3 are independently selected from H, OCH 3 or F; Ar 2 has a structure represented by a formula: wherein R 4a , R 4b and R 5 are independently selected from H, CN, F, Cl or OCF 3 , or a pharmaceutically acceptable salt, tautomer, geometrical isomer or optically active form thereof. 2. The compound of claim 1 wherein R1 is CF3. 3. The compound of claim 1 wherein R1is (CH 3 ) 2 CH. 4. The compound of claim 1 wherein R1 is cyclopropyl. 5. The compound according to claim 1 , selected from: N-(3-cyano-4-fluorophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-1-oxo-3-(pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-(cyclopropylmethyl)-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-7-fluoro-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-7-methoxy-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 2-isobutyl-1-oxo-3-(pyridin-3-yl)-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-2-isobutyl-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-6-fluoro-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 2-butyl-N-(3-cyano-4-fluorophenyl)-1-oxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-6-fluoro-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-1-oxo-3-(1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-7-fluoro-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyanophenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-5-fluorophenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; 2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-N-(3-(trifluoromethoxy)phenyl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(4-fluoro-3-(trifluoromethoxy)phenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-fluoro-5-(trifluoromethoxy)phenyl)-2-isobutyl-1-oxo-3-(1H-pyrazol-4-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-chloro-5-cyanophenyl)-7-fluoro-2-isobutyl-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-3-(isothiazol-4-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; N-(3-cyano-4-fluorophenyl)-2-isobutyl-1-oxo-3-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide; or N-(3-cyano-4-fluorophenyl)-1-oxo-3-(1H-pyrazol-4-yl-6,7-difluoro-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoqu

Assignees

Inventors

Classifications

  • Antimalarials · CPC title

  • Antiparasitic agents · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • C07D401/04Primary

    directly linked by a ring-member-to-ring-member bond · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9416124B2 cover?
In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl -1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not in…
Who is the assignee on this patent?
Guy Rodney Kiplin, Zhu Fangyi, Guiguemde Wendyam Armand, and 7 more
What technology area does this patent fall under?
Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).